Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis

Abstract

IMPORTANCE Even though osteoarthritis is a chronic and progressive disease, pharmacological agents are mainly studied over short-term periods, resulting in unclear recommendations for long-term disease management. OBJECTIVE To search, review, and analyze long-term (Ն12 months) outcomes (symptoms, joint structure) from randomized clinical trials (RCTs) of medications for knee osteoarthritis. DATA SOURCES AND STUDY SELECTION The databases of MEDLINE, Scopus, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials were searched until June 30, 2018 (MEDLINE alerts through August 31, 2018) for RCTs of patients with knee osteoarthritis that had treatment and follow-up lasting 1 year or longer. DATA EXTRACTION AND SYNTHESIS Data at baseline and at the longest available treatment and follow-up of 12 months' duration or longer (or the change from baseline) were extracted. A Bayesian random-effects network meta-analysis was performed. MAIN OUTCOMES AND MEASURES The primary outcome was the mean change from baseline in knee pain. Secondary outcomes were physical function and joint structure (the latter was measured radiologically as joint space narrowing). Standardized mean differences (SMDs) and mean differences with 95% credibility intervals (95% CrIs) were calculated. Findings were interpreted as associations when the 95% CrIs excluded the null value. RESULTS Forty-seven RCTs (22 037 patients; mean age range, mostly 55-70 years; and a higher mean proportion of women than men, around 70%) included the following medication categories: analgesics; antioxidants; bone-acting agents such as bisphosphonates and strontium ranelate; nonsteroidal anti-inflammatory drugs; intra-articular injection medications such as hyaluronic acid and corticosteroids; symptomatic slow-acting drugs in osteoarthritis such as glucosamine and chondroitin sulfate; and putative disease-modifying agents such as cindunistat and sprifermin. Thirty-one interventions were studied for pain, 13 for physical function, and 16 for joint structure. Trial duration ranged from 1 to 4 years. Associations with decreases in pain were found for the nonsteroidal anti-inflammatory drug celecoxib (SMD, −0.18 [95% CrI, −0.35 to −0.01]) and the symptomatic slow-acting drug in osteoarthritis glucosamine sulfate (SMD, −0.29 [95% CrI, −0.49 to −0.09]), but there was large uncertainty for all estimates vs placebo. The association with pain improvement remained significant only for glucosamine sulfate when data were analyzed using the mean difference on a scale from 0 to 100 and when trials at high risk of bias were excluded. Associations with improvement in joint space narrowing were found for glucosamine sulfate (SMD, −0.42 [95% CrI, −0.65 to −0.19]), chondroitin sulfate (SMD, −0.20 [95% CrI, −0.31 to −0.07]), and strontium ranelate (SMD, −0.20 [95% CrI, −0.36 to −0.05]). CONCLUSIONS AND RELEVANCE In this systematic review and network meta-analysis of studies of patients with knee osteoarthritis and at least 12 months of follow-up, there was uncertainty a...

Osteoarthritis year in review 2019: epidemiology and therapy

“…Therefore many patients ask for pharmacological treatments for a longer time period. Gregori et al performed a systematic review with Bayesian random effects network meta-analysis 16 . They included 31 placebo-and active-controlled randomized controlled trials with at least 12 months of follow-up in patients with knee OA.…”

Multifaceted Protective Role of Glucosamine against Osteoarthritis: Review of Its Molecular Mechanisms

“…Figure 1 summarizes the molecular mechanisms of glucosamine in protecting against osteoarthritis. Studies showed that glucosamine did not improve OA [130][131][132][133][134][135][136]. Roman-Blas et al treated rabbits with OA with a combination of glucosamine sulphate (1500 mg) and chondroitin sulphate (1200 mg) daily for 2 weeks [130].…”

“…After 6 weeks, the group receiving glucosamine treatment showed no difference in all signs and symptoms of OA compared with those of the placebo group [133]. Furthermore, several meta-analyses also showed either negligible [134] or small pain-relieving effects of glucosamine in OA patients [135,136]. The discrepancies in the effectiveness of glucosamine on OA between various studies should be further examined.…”

Dolor en la Artrosis de Rodilla

“…Con relación a la segunda línea el tiempo de espera para evaluar la respuesta debe ser al menos de seis semanas. 51,52 Las escalas descritas para la gradación del dolor son múltiples, pero confirman que ese síntoma es el más importante de todos, y que además facilita evaluar los métodos de tratamiento empleados en esos enfermos.…”